Recent evidence indicates frequent mutation in histone modifying proteins and dysregulation of PI3K pathway in non-Hodgkin lymphoma (NHL), particularly in diffuse large B-cell lymphoma (DLBCL). Here, PIK3CB is linked to non-Hodgkin lymphoma.